GLAND.NS
GLAND.NS
INE068V01023
GLAND PHARMA LIMITED
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±36.7% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.6x).

Beta (Market Relation)
0.58x
Defensive
Volatility (5Y p.a.)
36.7% p.a.
5-Year Horizon
Max Drawdown (5Y)
-77.5%
5-Year Horizon
Sharpe Ratio
-0.19
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +57.3%
3 Years 31.6% -35.0% 0.68 +24%
5 Years 36.7% -77.5% -0.19 -4.4%
10 Years — — — —

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (36.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -77.5% in the extended horizon.
ende